CanSino Biologics Inc. (CANSINOBIO) has scheduled its 2025 Annual General Meeting (AGM) for 10 June 2026 in Tianjin. Shareholders will vote on 15 resolutions that cover performance review, profit allocation, capital management and governance updates.
Key agenda items:
• 2025 Financials and Board Report The Board will present the 2025 Annual Report, disclosing net profit attributable to shareholders of RMB 27.87 million and accumulated losses of RMB 471.44 million.
• Profit Distribution Given the carried-forward deficit, the Board proposes no dividend or capitalisation of reserves for 2025.
• Three-Year Dividend Policy (2026-2028) A new framework prioritises cash dividends, setting minimum payout thresholds linked to profitability and future capital requirements. Specific cash dividend ratios range from 20 % to 80 % depending on development stage, profit and investment needs.
• Auditor Re-appointment Deloitte Touche Tohmatsu Certified Public Accountants LLP (PRC) and Deloitte Touche Tohmatsu (international) are nominated as external auditors for 2026. Total audit and internal-control fees are estimated at RMB 3.65 million.
• Bank Credit Lines The Company seeks approval to renew and/or increase bank facilities up to RMB 2.70 billion (or foreign-currency equivalent) for 2026.
• FX Hedging Programme Management requests authority to conduct foreign-exchange hedging transactions with a contract cap of RMB 840 million and a maximum margin/premium outlay of RMB 84 million during the mandate period.
• Share Issuance Authorities 1) General mandate to issue up to 20 % of existing share capital in A or H Shares. 2) Separate mandate under Shanghai STAR Market’s simplified procedure to place A Shares raising up to RMB 300 million (≤20 % of latest year-end net assets).
• Share Repurchase Mandate Authorisation to buy back up to 10 % of total issued A and/or H Shares (excluding treasury shares) during the mandate period.
• Debt Financing Permission to issue onshore or offshore debt instruments (short-term, medium-term, bonds or notes) up to RMB 1.00 billion (or foreign-currency equivalent) with maturities of up to ten years.
• Governance Amendments Updates to the Articles of Association and procedural rules include stricter director eligibility, enhanced disclosure for related-party transactions, and refined board and shareholder-meeting processes.
• Other Resolutions Shareholders will consider uncovered deficit acknowledgment, purchase of directors’ and officers’ liability insurance (coverage up to USD 20 million), a new remuneration management system for directors and senior executives, and reappointment of the internal-control audit agency.
Record Date & Proxy H-shareholders registered by 10 June 2026 may attend and vote. Proxy forms must be lodged by 1:30 p.m. on 9 June 2026.
The AGM notice emphasizes that completion of proxy forms does not preclude shareholders from voting in person.